Showing 1881-1890 of 4063 results for "".
- Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Studyhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-of-netarsudil-ophthalmic-solution-in-pilot-phase-2-study/2476219/Aerie Pharmaceuticals announced the topline results of its pilot phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regu
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Studyhttps://modernod.com/news/eyenovia-completes-patient-enrollment-in-microstat-mist-1-study-and-enrolls-first-patient-in-mist-2-study/2476167/Eyenovia announced that it has completed patient enrollment in its phase 3 MIST-1 study and enrolled the first patient in its second phase 3 study, the MIST-2 trial, for the company’s phase 3 MicroStat program for pharmacologic mydriasis. “We are pleased to
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011https://modernod.com/news/aura-biosciences-reports-positive-phase-1b-2-clinical-data-for-au-011/2479713/Aura Biosciences has reported positive clinical data from its phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma. “Ocular melanoma is the most
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAOhttps://modernod.com/news/aura-biosciences-to-present-phase-1b-2-clinical-data-for-au-011-at-aao/2479786/Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27
- Oxurion Enrolls First Patient in Phase 2 Study Evaluating THR-317 for Treatment of Idiopathic Macular Telangiectasia Type 1https://modernod.com/news/oxurion-enrolls-first-patient-in-phase-2-study-evaluating-thr-317-for-treatment-of-idiopathic-macular-telangiectasia-type-1/2479863/Oxurion, formerly ThromboGenics, announced that it has enrolled the first patient in a phase 2 open-label multicenter study evaluating the efficacy and safety of intravitreal THR-317, an anti-PIGF (human placental growth factor) antibody, for the treatment of Macular Telangiectasia Type 1 (MacTel
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the